Canada: Section 8 Proceedings - Damages Awarded And Quantified (Intellectual Property Weekly Abstracts Bulletin - Week Of May 7, 2012)

Last Updated: May 31 2012
Most Read Contributor in Canada, September 2016

Edited by Chantal Saunders and Beverley Moore


Section 8 Damages Awarded and Quantified

Apotex v. Sanofi 2012 FC 553

Drug: ramipril

In this quantification of s. 8 damages owed to Apotex by Sanofi, the Court first summarized the history of all the Notice of Compliance (NOC) proceedings that lead to this case pursuant to section 8 of the NOC Regulations. A number of factual and legal issues were also discussed.

The start date of the damages period was under dispute. Apotex had sent two separate Notices of Allegation (NOAs) in relation to one patent on the Patent Register; one alleging non-infringement and the second alleging invalidity. Proceedings were started in both cases, and prohibition was granted in the infringement allegation. However, the second proceeding resulted in a finding that Apotex' allegation of invalidity was justified. The Court held that, if Apotex had pursued the invalidity and the non-infringement allegations in the same NOA, there would not have been a Prohibition Order. Thus, Sanofi was not entitled to rely on the Prohibition Order with respect to the non-infringement allegation for the purposes of determining the start date for s. 8 damages. As a result, the Court held that the date Apotex' Apo-Ramipril product was put on patent hold was the appropriate date to begin the liability period.

The parties also disputed the end date for the damages period. Apotex argued that it should extend until the last NOC proceeding was dismissed. However, Apotex had received its NOC prior to that date as the Minister had determined that Apotex was no longer required to address the patents listed on the Patent Register. The Court held that the date the last prohibition proceeding was dismissed was really an arbitrary date as it had become moot when Apotex received its NOC. The end date was held to be the date the NOC issued.

The Court then considered the size of the generic market and Apotex' share of the generic market. The Court held that once the generic company leads prima facia evidence of its losses, the evidential burden shifts to the innovator to show that other generics would have entered the market. The Court considered the timing of the launch of other generics that were sending NOAs during the relevant period. The Court also considered the timing of the launch of an authorized generic. The Court looked at the price of the generic medicine during the relevant time periods as well as Apotex' costs. The Court held that Apotex was not entitled to claim for damages in the ramp-up period that occurred after the relevant period. Finally, the Court did not reduce the damages for sales associated with unapproved uses.

Section 8 Damages Quantified to Second Generic Company

Sanofi-aventis v. Teva 2012 FC 552

Drug: ramipril

This was a second s. 8 damages quantification relating to ramipril; however with a different generic company as plaintiff. This proceeding was heard separately from the proceeding above, and the decision was made on a different factual record.

The parties also disputed the start date for the relevant period. In this case, Teva had received Drug Identification Numbers for its product and its certification letter for approvability prior to the commencement of the first NOC proceeding. However, Teva had also agreed to wait until the expiry of one patent listed on the Patent Register before entering the market. The Court held that, because Teva had elected not to challenge one of the patents on the Patent Register, the start date for the damages period commenced when that patent expired.

The Court then determined the overall sizes of the ramipril market and the generic ramipril market. Teva's claims for "lost business value" were rejected as the Court held that these were losses that occurred after the relevant period. Similarly, Teva was not permitted to claim for the rampup period that occurred outside the relevant period. The claim for lost profits on sales of Teva's other products was not allowed. Similarly, Teva's lost indirect profits were not allowed. Finally, no downward adjustment was made for sales Teva made for unapproved uses.

Validity of Section 8 Upheld

Apotex Inc. v. Sanofi-Aventis; Teva Canada Limited v. Sanofi-Aventis 2012 FC 551

Drug: ramipril

Sanofi challenged the validity of section 8 in two actions, summarized above (Teva and Apotex). The validity arguments raised in these two proceedings were noted to be identical to those raised in another action involving AstraZeneca, summarized below. Accordingly, the validity issues were argued before the two judges together in each of the Sanofi actions and the AstraZeneca action.

The Court rejected Sanofi's challenges to the validity of section 8, finding that the general validity of section 8 was determined by the Federal Court of Appeal in a previous decision. The Court then considered and rejected additional validity issues raised by Sanofi that were not specifically addressed in the Court of Appeal's decision.

Entitlement to Section 8 Damages Determined

Apotex Inc. v. AstraZeneca Canada Inc. 2012 FC 559

Drug: omeprazole

The trial was divided into two parts, with AstraZeneca's challenges relating to the validity of section 8 being argued before the Trial Judge and a second judge seized with many of the same validity challenges in two unrelated matters (summarized above). Further, the experts on the evidentiary issues were examined in a "hot tubbing" format after being questioned in the usual manner, with the Trial Judge asking questions and each expert responding to comments made by the other. Counsel was then permitted to pose follow-up questions.

The trial related to entitlement and other issues relating to section 8, and a Reference is to be held relating to quantification of damages.

The Court rejected AstraZeneca's challenges to the validity of section 8. The Court also rejected AstraZeneca's arguments that Apotex did not meet the definition of "second person" so as to trigger section 8. With respect to AstraZeneca's argument that the alleged infringement of the patent is relevant, the Court held that the judge hearing the pending infringement action could craft a remedy so as to take into consideration the findings and awards made pursuant to section 8 as it would be unconscionable to delay these proceedings in any way until the infringement matter was heard and decided.

The remaining issues related to the date of approvability for Apotex' product and whether circumstances existed to change the date. In particular, the Court held that Apotex had the capacity to manufacture its omeprazole product at two sites, even though only one had been approved by Health Canada. Apotex could have simply advised Health Canada that it was moving its manufacturing operation to the second site and Health Canada would have worked with Apotex to issue a "no objection" letter.

In conclusion, the Court ordered that Apotex is entitled to be compensated for its loss suffered by virtue of the NOC proceedings and that there is no basis to reduce or refuse such compensation.


Patent Application Claiming Method for Making Antibodies Allowed in Part

Commissioner's Decision No. 1323

The patent application was rejected by the Examiner on the basis that the claims are broader than the teaching of the description, contrary to section 84 of the Patent Rules and section 27(3) of the Patent Act. The Patent Appeal Board (PAB) considered that two questions were to be determined: do the method claims go beyond the limits of a sound prediction; and is the disclosure sufficient such that the product claims do not exceed what has been described and enabled by the specification.

In particular, the PAB held that utility is called into question in light of the reason for the refusal, even though not specifically stated in the Final Action. Accordingly, the PAB considered whether the method claims were soundly predicted. The PAB concluded that the facts provided and the line of reasoning set out in the application, combined with the fact that no scientific rationale was provided that would weigh against the line of reasoning, would allow a person skilled in the art to soundly predict that some of the methods would produce the antibody of interest. Accordingly, these claims were allowed by the Commissioner. However, there were other method claims that could not be soundly predicted. The Commissioner of Patents (Commissioner) invited the Applicant to amend these claims.

The PAB further concluded that undue experimentation would not be required by the person skilled in the art to practice the claimed method.

Obviousness Assessment of Patent Application

Commissioner's Decision No. 1324

The PAB considered a patent application relating to a device and method for use in training firefighters in the extinguishment of a fuel spill fire. The application had been rejected on the basis of obviousness. The PAB reviewed the prior art references and the Commissioner invited the Applicant to make a number of amendments in light of the findings by the PAB that some of the claims are obvious.

Patent Application Rejected Again for Obviousness

Commissioner's Decision No. 1325

The Commissioner had previously refused the patent application on the basis of obviousness. On appeal, the Court ordered the redetermination of obviousness. The Commissioner again refused the application, and the Court again ordered redetermination after noting several errors made in the refusal. The patent application relates to a subway TV media system.

The PAB again found the claims to be obvious after considering the prior art and the expert evidence provided by the Applicant, and the Commissioner refused to grant the patent.


The Natural Health Products Directorate (NHPD) is seeking feedback on proposed revisions to the existing guidance document titled Evidence for Safety and Efficacy of Finished Natural Health Products. It has been replaced by two proposed guidance documents: Pathway for Licensing Natural Health Products Making Modern Health Claims and Pathway for Licensing Natural Health Products Used as Traditional Medicines. The consultation period is open until August 21, 2012.

Health Canada has released two new Guidance documents: Guidance on Conduct and Analysis of Comparative Bioavailability Studies and Guidance on Comparative Bioavailability Standards: Formulations Used for Systemic Effects.

CIPO has posted comments received regarding its Consultation for the Practice Respecting Inventive Concept, Statutory Subject Matter under the Patent Act, and Claims to Diagnostic Methods and Medical Uses.

About BLG

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.